Rosinsulin was traditionally presented at the X (XXXI) National Diabetes Congress in Moscow

The X (XXXI) National Diabetes Congress with international participation was held in Moscow from May 27 to 30, 2025. The event was dedicated to the topic «Diabetes mellitus – a non-infectious pandemic of the 21st century. Macro- and microvascular complications. Issues of interdisciplinary interaction». The Congress was dedicated to the 100th anniversary of the Russian Association of Endocrinologists, the Endocrinology Service of the Russian Federation and the Research Center for Endocrinology.

Medsintez Plant, one of the leading Russian manufacturers of pharmaceutical products, presented a range of genetically engineered and analogue human insulins – Rosinsulin. Doctors who visited the exhibition noted the high quality and availability of the company's products.

As part of the business program, Ivan Dedov, President of the National Medical Research Center for Endocrinology, noted that a total of 12 million people with diabetes in Russia may need medical assistance. This number includes both currently existing patients and potential ones.

For over 15 years, Medsintez Plant has been ensuring the drug safety of Russia by producing insulins that meet international GMP standards. The company became one of the first manufacturers in the country to master the full-cycle production of genetically engineered insulin. The production capacity of the plant allows meeting 100% of the country’s needs for insulin drugs.

Photo: IZVESTIA/Eduard Kornienko

Today, Medsintez Plant produces a full range of genetically engineered human insulin Rosinsulin and its analogue forms – Rosinsulin Aspart R and Rosinsulin Glargine from its own substances. It assures the complete independence from foreign manufacturers and stable product prices.

The production process of the plant meets international quality standards. In 2007, Medsintez Plant received the Russian Government Award for Quality. Clinical trials have confirmed the bioequivalence and interchangeability of Rosinsulin drugs with foreign analogues. The drugs are available in convenient dosage forms: vials, cartridges and pre-filled syringes.

The company pays particular attention to the convenience of patients: It has developed and patented disposable and reusable syringe pens for precise dosing. In addition, work on improvement of these devices never stops.

The company is actively developing in the direction of increasing the range of insulin drugs. It has become possible due to our own facilities for creating and producing devices for administering drugs, as well as the availability of research resources and expertise in the field of biotechnology.

Photo: IZVESTIA/Eduard Kornienko

Supported by the Industrial Development Fund, Medsintez Plant plans to launch the production of the hypoglycemic drug Semaglutide (analogue to Ozempic) for the treatment of type 2 diabetes, which will help eliminate the shortage caused by the cessation of supplies from abroad. Type 2 diabetes accounts for 90% of all diabetes cases today, making it particularly important to provide Russian patients with advanced treatment technologies at this time.

In addition, the exhibit booth of the plant highlighted a new dosage form of the analogue insulin Rosinsulin Aspart with dose increments of 0.33 IU and 0.5 IU and cartridge volume of 1.5 ml in syringe pens, which is particularly in demand among pediatric endocrinologists. The dose increments of 0.33 IU and 0.5 IU allow for more accurate drug dose selection in the first year of insulin therapy in patients with diabetes mellitus.

As part of the business program of the Congress, professionals discussed innovative methods of diagnosing and treating diabetes, and also considered key topics such as the development of the endocrinology service in the regions, epidemiology and state diabetes registries, diabetes in children and adolescents, multidisciplinary approach to managing patients with type 2 diabetes, and other relevant issues.